[HER2 expression in gastric cancer in Peru]

HER2 positivity is thought to be a negative prognostic factor in gastric cancer (GC), correlating with poor survival rates. Reported HER2-positivity rates in GC have varied widely (6-35%). Objective of this study is to determine rate of positivity and describe clinical and pathological characteristics of HER-2(+) GC. 100 GC tumour samples were centrally screened by immunohistochemistry and FISH. 9% of cases were positive. More positivity HER2 was found in advanced stages (III/IV) vs. early stages (I/II)(p=0.045) ; intestinal histology subtype vs diffuse/ mixed (p=0.045) and gastro-oesophageal junction cancer vs GC ( p=0.005).